bupropion has been researched along with Overweight in 23 studies
Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.
Overweight: A status with BODY WEIGHT that is above certain standards. In the scale of BODY MASS INDEX, overweight is defined as having a BMI of 25.0-29.9 kg/m2. Overweight may or may not be due to increases in body fat (ADIPOSE TISSUE), hence overweight does not equal over fat.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A reduction in BMI z-score during smoking cessation with bupropion has important implications for the future of adolescent smoking cessation." | 9.22 | BMI changes in adolescents treated with bupropion SR for smoking cessation. ( Floden, L; Leischow, SJ; Muramoto, ML; Taren, DL, 2016) |
| "To determine whether the combination of naltrexone and bupropion increases major adverse cardiovascular events (MACE, defined as cardiovascular death, nonfatal stroke, or nonfatal myocardial infarction) compared with placebo in overweight and obese patients." | 9.22 | Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial. ( Bakris, G; Buse, JB; Nissen, SE; Perez, A; Prcela, L; Smith, SR; Wadden, T; Wolski, KE, 2016) |
| "CONTRAVE Obesity Research-II (COR-II) was a double-blind, placebo-controlled study of 1,496 obese (BMI 30-45 kg/m(2) ) or overweight (27-45 kg/m(2) with dyslipidemia and/or hypertension) participants randomized 2:1 to combined naltrexone sustained-release (SR) (32 mg/day) plus bupropion SR (360 mg/day) (NB32) or placebo for up to 56 weeks." | 9.17 | A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). ( Apovian, CM; Aronne, L; Burns, C; Dunayevich, E; Kim, D; Rubino, D; Still, C; Wyatt, H, 2013) |
| " The objective of this study was to perform a randomized placebo-controlled trial to evaluate the short-term efficacy of bupropion for the treatment of BED in overweight and obese women." | 9.17 | Bupropion for overweight women with binge-eating disorder: a randomized, double-blind, placebo-controlled trial. ( Grilo, CM; White, MA, 2013) |
| "To assess the efficacy and safety of 32 mg naltrexone sustained-release (SR)/360 mg bupropion SR (NB) in overweight/obese individuals with type 2 diabetes with or without background oral antidiabetes drugs." | 9.17 | Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. ( Bays, H; Burns, C; Fujioka, K; Greenway, F; Gupta, AK; Hollander, P; Klassen, P; Plodkowski, R, 2013) |
| "A combination of sustained release (SR) naltrexone (32 mg/day) and bupropion SR (360 mg/day) plus behavioral counseling was evaluated for the treatment of smoking cessation and mitigation of nicotine withdrawal and weight gain." | 9.14 | An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects. ( Billes, SK; Dunayevich, E; Erickson, JS; Katz, BB; Oskooilar, N; Tollefson, G; Wilcox, CS, 2010) |
| "A sustained-release combination of naltrexone plus bupropion could be a useful therapeutic option for treatment of obesity." | 9.14 | Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. ( Dunayevich, E; Erickson, J; Fujioka, K; Greenway, FL; Guttadauria, M; Kim, DD; Mudaliar, S; Plodkowski, RA, 2010) |
| "This review covers the development of naltrexone/bupropion combination therapy for obesity, as well as the published clinical trials on the safety and efficacy of the combination in overweight and obese humans." | 8.87 | Combination therapy with naltrexone and bupropion for obesity. ( Billes, SK; Greenway, FL, 2011) |
| "To investigate the changes of circulating levels of all proglucagon-derived peptides (PGDPs) in individuals with overweight or obesity receiving liraglutide (3 mg) or naltrexone/bupropion (32/360 mg), and to explore the association between induced changes in postprandial PGDP levels and body composition, as well as metabolic variables, after 3 and 6 months on treatment." | 8.31 | Circulating levels of proglucagon-derived peptides are differentially regulated by the glucagon-like peptide-1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6-month long ( Argyrakopoulou, G; Bontozoglou, N; Kalra, B; Kokkinos, A; Konstantinidou, SK; Kouvari, M; Kumar, A; Kumar, M; Kyriakopoulou, K; Mantzoros, CS; Simati, S; Stefanakis, K, 2023) |
| "A reduction in BMI z-score during smoking cessation with bupropion has important implications for the future of adolescent smoking cessation." | 5.22 | BMI changes in adolescents treated with bupropion SR for smoking cessation. ( Floden, L; Leischow, SJ; Muramoto, ML; Taren, DL, 2016) |
| "To determine whether the combination of naltrexone and bupropion increases major adverse cardiovascular events (MACE, defined as cardiovascular death, nonfatal stroke, or nonfatal myocardial infarction) compared with placebo in overweight and obese patients." | 5.22 | Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial. ( Bakris, G; Buse, JB; Nissen, SE; Perez, A; Prcela, L; Smith, SR; Wadden, T; Wolski, KE, 2016) |
| "CONTRAVE Obesity Research-II (COR-II) was a double-blind, placebo-controlled study of 1,496 obese (BMI 30-45 kg/m(2) ) or overweight (27-45 kg/m(2) with dyslipidemia and/or hypertension) participants randomized 2:1 to combined naltrexone sustained-release (SR) (32 mg/day) plus bupropion SR (360 mg/day) (NB32) or placebo for up to 56 weeks." | 5.17 | A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). ( Apovian, CM; Aronne, L; Burns, C; Dunayevich, E; Kim, D; Rubino, D; Still, C; Wyatt, H, 2013) |
| " The objective of this study was to perform a randomized placebo-controlled trial to evaluate the short-term efficacy of bupropion for the treatment of BED in overweight and obese women." | 5.17 | Bupropion for overweight women with binge-eating disorder: a randomized, double-blind, placebo-controlled trial. ( Grilo, CM; White, MA, 2013) |
| "To assess the efficacy and safety of 32 mg naltrexone sustained-release (SR)/360 mg bupropion SR (NB) in overweight/obese individuals with type 2 diabetes with or without background oral antidiabetes drugs." | 5.17 | Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. ( Bays, H; Burns, C; Fujioka, K; Greenway, F; Gupta, AK; Hollander, P; Klassen, P; Plodkowski, R, 2013) |
| " Here, we explore combination therapy with bupropion (BUP), a putative stimulator of melanocortin pathways, and an opioid antagonist, naltrexone (NAL), to antagonize an inhibitory feedback loop that limits sustained weight reduction." | 5.14 | Rational design of a combination medication for the treatment of obesity. ( Anderson, JW; Atkinson, RL; Cowley, MA; Dunayevich, E; Fujioka, K; Gadde, KM; Greenway, FL; Gupta, AK; Guttadauria, M; O'Neil, P; Schumacher, D; Smith, D; Tollefson, GD; Weber, E; Whitehouse, MJ, 2009) |
| "A combination of sustained release (SR) naltrexone (32 mg/day) and bupropion SR (360 mg/day) plus behavioral counseling was evaluated for the treatment of smoking cessation and mitigation of nicotine withdrawal and weight gain." | 5.14 | An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects. ( Billes, SK; Dunayevich, E; Erickson, JS; Katz, BB; Oskooilar, N; Tollefson, G; Wilcox, CS, 2010) |
| "A sustained-release combination of naltrexone plus bupropion could be a useful therapeutic option for treatment of obesity." | 5.14 | Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. ( Dunayevich, E; Erickson, J; Fujioka, K; Greenway, FL; Guttadauria, M; Kim, DD; Mudaliar, S; Plodkowski, RA, 2010) |
| "This review covers the development of naltrexone/bupropion combination therapy for obesity, as well as the published clinical trials on the safety and efficacy of the combination in overweight and obese humans." | 4.87 | Combination therapy with naltrexone and bupropion for obesity. ( Billes, SK; Greenway, FL, 2011) |
| "Contrave is an investigational fixed-dose combination drug of naltrexone and bupropion currently in Phase III clinical trials for the treatment of obesity." | 4.87 | ACS chemical neuroscience molecule spotlight on contrave. ( Mercer, SL, 2011) |
| "To investigate the changes of circulating levels of all proglucagon-derived peptides (PGDPs) in individuals with overweight or obesity receiving liraglutide (3 mg) or naltrexone/bupropion (32/360 mg), and to explore the association between induced changes in postprandial PGDP levels and body composition, as well as metabolic variables, after 3 and 6 months on treatment." | 4.31 | Circulating levels of proglucagon-derived peptides are differentially regulated by the glucagon-like peptide-1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6-month long ( Argyrakopoulou, G; Bontozoglou, N; Kalra, B; Kokkinos, A; Konstantinidou, SK; Kouvari, M; Kumar, A; Kumar, M; Kyriakopoulou, K; Mantzoros, CS; Simati, S; Stefanakis, K, 2023) |
| "The recent approval of liraglutide, lorcaserin, naltrexone/bupropion extended-release, and phentermine/topiramate extended-release, brings the number of medications for long-term weight loss to 5 (including orlistat)." | 3.83 | Answers to Clinical Questions in the Primary Care Management of People with Obesity: Pharmacologic Management. ( Braverman-Panza, J; Fujioka, K, 2016) |
| " Lorcaserin (Belviq(®)), phentermine/topiramate combination (Qsymia(®)), and bupropion/naltrexone combination have been demonstrated to be effective for the treatment of obesity, as an adjunct to a reduced-calorie diet and physical activity, although their absolute safety has yet to be established with more widespread use or longer use." | 3.79 | Therapies for obesity and medication-associated weight gain. ( Howland, RH, 2013) |
| " However, they are costly and may have adverse effects in some individuals." | 2.72 | Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand? ( Lee, SY; Tak, YJ, 2021) |
| " Central nervous system-active medications have the potential to affect mood; therefore, post hoc analysis of clinical trial data was conducted to evaluate psychiatric adverse events (PAEs) and effects on mood of NB therapy versus placebo." | 1.51 | Psychiatric adverse events and effects on mood with prolonged-release naltrexone/bupropion combination therapy: a pooled analysis. ( Acevedo, LM; Apovian, CM; Dunayevich, E; Greenway, FL; McElroy, SL; Pi-Sunyer, X, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (4.35) | 29.6817 |
| 2010's | 20 (86.96) | 24.3611 |
| 2020's | 2 (8.70) | 2.80 |
| Authors | Studies |
|---|---|
| Stefanakis, K | 1 |
| Kokkinos, A | 1 |
| Argyrakopoulou, G | 1 |
| Konstantinidou, SK | 1 |
| Simati, S | 1 |
| Kouvari, M | 1 |
| Kumar, A | 1 |
| Kalra, B | 1 |
| Kumar, M | 1 |
| Bontozoglou, N | 1 |
| Kyriakopoulou, K | 1 |
| Mantzoros, CS | 1 |
| Tak, YJ | 1 |
| Lee, SY | 1 |
| Guerdjikova, AI | 1 |
| Walsh, B | 1 |
| Shan, K | 1 |
| Halseth, AE | 2 |
| Dunayevich, E | 6 |
| McElroy, SL | 2 |
| Jha, MK | 1 |
| Wakhlu, S | 1 |
| Dronamraju, N | 1 |
| Minhajuddin, A | 1 |
| Greer, TL | 1 |
| Trivedi, MH | 1 |
| Pi-Sunyer, X | 1 |
| Apovian, CM | 2 |
| Acevedo, LM | 1 |
| Greenway, FL | 4 |
| Aronne, L | 1 |
| Rubino, D | 1 |
| Still, C | 1 |
| Wyatt, H | 1 |
| Burns, C | 2 |
| Kim, D | 1 |
| Howland, RH | 1 |
| White, MA | 1 |
| Grilo, CM | 1 |
| Hollander, P | 1 |
| Gupta, AK | 2 |
| Plodkowski, R | 1 |
| Greenway, F | 1 |
| Bays, H | 1 |
| Klassen, P | 1 |
| Fujioka, K | 5 |
| Nau, JY | 1 |
| Greig, SL | 1 |
| Keating, GM | 1 |
| McGinty, EE | 1 |
| Baller, J | 1 |
| Azrin, ST | 1 |
| Juliano-Bult, D | 1 |
| Daumit, GL | 1 |
| Floden, L | 1 |
| Taren, DL | 1 |
| Muramoto, ML | 1 |
| Leischow, SJ | 1 |
| Nissen, SE | 1 |
| Wolski, KE | 1 |
| Prcela, L | 1 |
| Wadden, T | 1 |
| Buse, JB | 1 |
| Bakris, G | 1 |
| Perez, A | 1 |
| Smith, SR | 1 |
| Hong, K | 1 |
| Herrmann, K | 1 |
| Dybala, C | 1 |
| Lam, H | 1 |
| Foreyt, JP | 1 |
| Braverman-Panza, J | 1 |
| Whitehouse, MJ | 1 |
| Guttadauria, M | 2 |
| Anderson, JW | 1 |
| Atkinson, RL | 1 |
| Gadde, KM | 1 |
| O'Neil, P | 1 |
| Schumacher, D | 1 |
| Smith, D | 1 |
| Tollefson, GD | 1 |
| Weber, E | 1 |
| Cowley, MA | 1 |
| Wilcox, CS | 1 |
| Oskooilar, N | 1 |
| Erickson, JS | 1 |
| Billes, SK | 2 |
| Katz, BB | 1 |
| Tollefson, G | 1 |
| Plodkowski, RA | 1 |
| Mudaliar, S | 1 |
| Erickson, J | 1 |
| Kim, DD | 1 |
| Calandra, C | 1 |
| Russo, RG | 1 |
| Luca, M | 1 |
| Mercer, SL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Multicenter, Randomized, Double Blind, Placebo Controlled Study Comparing the Safety and Efficacy of Naltrexone Sustained Release (SR)/Bupropion Sustained Release (SR) and Placebo in Obese Subjects[NCT00567255] | Phase 3 | 1,496 participants (Actual) | Interventional | 2007-12-31 | Completed | ||
| Placebo-Controlled Trial of Bupropion for the Treatment of Binge Eating Disorder[NCT00414167] | Phase 2/Phase 3 | 61 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| A Multicenter, Randomized, Double Blind, Placebo Controlled Study Comparing the Safety and Efficacy of Naltrexone 32 mg Sustained Release (SR)/Bupropion 360 mg Sustained Release (SR) and Placebo in Obese Subjects With Type 2 Diabetes Mellitus[NCT00474630] | Phase 3 | 505 participants (Actual) | Interventional | 2007-05-31 | Completed | ||
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Assessing the Occurrence of Major Adverse Cardiovascular Events (MACE) in Overweight and Obese Subjects With Cardiovascular Risk Factors Receiving Naltrexone SR/Bupropion SR[NCT01601704] | Phase 3 | 8,910 participants (Actual) | Interventional | 2012-06-30 | Terminated | ||
| A Multicenter, Randomized, Double Blind, Placebo Controlled Study Comparing the Safety and Efficacy of Two Doses of Naltrexone Sustained Release (SR)/Bupropion Sustained Release (SR) and Placebo in Obese Subjects[NCT00532779] | Phase 3 | 1,742 participants (Actual) | Interventional | 2007-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
"Beginning at Week 28 through Week 44, NB32-treated subjects who failed to achieve or maintain at least 5% body weight loss from baseline were re-randomized (1:1 ratio) to continue NB32 or begin treatment with a higher dose of naltrexone SR - naltrexone SR 48 mg/bupropion SR 360 mg (referred to as NB48) (daily dose of bupropion SR was 360 mg for NB32 and NB48).The analysis of NB32 vs. placebo at Week 56 was completed using a weighted analysis. This analysis was referred to as the weighted LOCF analysis.~Subjects treated with NB32 who were re-randomized to NB48 were not included. Subjects re-randomized to NB32 were double-weighted and subjects who were not re-randomized were single-weighted. Subjects in the placebo group were single-weighted. The double weighting analysis restored the influence of poor performers at Weeks 28 to 44 in the NB32 group without including any data from the higher dose group (NB48)." (NCT00567255)
Timeframe: Baseline, 56 weeks
| Intervention | percentage of body weight (Least Squares Mean) |
|---|---|
| NB32 | -6.40 |
| Placebo | -1.23 |
(NCT00567255)
Timeframe: Baseline, 28 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| NB32 | 27.27 |
| Placebo | 7.02 |
"Beginning at Week 28 through Week 44, NB32-treated subjects who failed to achieve or maintain at least 5% body weight loss from baseline were re-randomized (1:1 ratio) to continue NB32 or begin treatment with a higher dose of naltrexone SR - naltrexone SR 48 mg/bupropion SR 360 mg (referred to as NB48) (daily dose of bupropion SR was 360 mg for NB32 and NB48).The analysis of NB32 vs. placebo at Week 56 was completed using a weighted analysis. This analysis was referred to as the weighted LOCF analysis.~Subjects treated with NB32 who were re-randomized to NB48 were not included. Subjects re-randomized to NB32 were double-weighted and subjects who were not re-randomized were single-weighted. Subjects in the placebo group were single-weighted. The double weighting analysis restored the influence of poor performers at Weeks 28 to 44 in the NB32 group without including any data from the higher dose group (NB48)." (NCT00567255)
Timeframe: Baseline, 56 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| NB32 | 50.48 |
| Placebo | 17.11 |
(NCT00567255)
Timeframe: Baseline, 28 weeks
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| NB32 | 0.20 |
| Placebo | -0.67 |
(NCT00567255)
Timeframe: Baseline, 28 weeks
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| NB32 | -2.11 |
| Placebo | -1.73 |
(NCT00567255)
Timeframe: Baseline, 28 weeks
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| NB32 | 1.19 |
| Placebo | -1.40 |
(NCT00567255)
Timeframe: Baseline, 28 weeks
| Intervention | percent change (Least Squares Mean) |
|---|---|
| NB32 | -14.14 |
| Placebo | -0.50 |
(NCT00567255)
Timeframe: Baseline, 28 weeks
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| NB32 | -4.36 |
| Placebo | 0.00 |
(NCT00567255)
Timeframe: Baseline, 28 weeks
| Intervention | percent change (Least Squares Mean) |
|---|---|
| NB32 | -7.32 |
| Placebo | -1.36 |
The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The carbohydrates subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome). (NCT00567255)
Timeframe: Baseline, 28 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| NB32 | -2.68 |
| Placebo | -2.20 |
The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The sweets subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome). (NCT00567255)
Timeframe: Baseline, 28 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| NB32 | -3.20 |
| Placebo | -3.18 |
(NCT00567255)
Timeframe: Baseline, 28 weeks
| Intervention | percent change (Least Squares Mean) |
|---|---|
| NB32 | -9.38 |
| Placebo | -1.14 |
HOMA-IR= Homeostasis Model Assessment-Insulin Resistance (NCT00567255)
Timeframe: Baseline, 28 weeks
| Intervention | percent change (Least Squares Mean) |
|---|---|
| NB32 | -16.44 |
| Placebo | -4.15 |
IDS-SR= Inventory of Depressive Symptoms-Subject Rated IDS-SR total score is based on 30 items. The total score can range from 0-84, with 0 being no depressive symptoms and 84 being very severe depressive symptoms. A total score ≤ 13 indicates no depression. (NCT00567255)
Timeframe: Baseline, 28 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| NB32 | -0.23 |
| Placebo | -0.28 |
IWQOL-Lite= Impact of Weight on Quality of Life-Lite Questionnaire Total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment (NCT00567255)
Timeframe: Baseline, 28 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| NB32 | 9.94 |
| Placebo | 6.17 |
Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult (NCT00567255)
Timeframe: Baseline, 28 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| NB32 | -18.32 |
| Placebo | -11.09 |
(NCT00567255)
Timeframe: Baseline, 28 weeks
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| NB32 | -0.93 |
| Placebo | -1.23 |
(NCT00567255)
Timeframe: Baseline, 28 weeks
| Intervention | cm (Least Squares Mean) |
|---|---|
| NB32 | -6.16 |
| Placebo | -2.74 |
(NCT00567255)
Timeframe: Baseline, 28 weeks
| Intervention | percentage of body weight (Least Squares Mean) |
|---|---|
| NB32 | -6.45 |
| Placebo | -1.89 |
(NCT00567255)
Timeframe: Baseline, 28 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| NB32 | 55.64 |
| Placebo | 17.54 |
(NCT00414167)
Timeframe: One week (at post treatment)
| Intervention | episodes/week (Mean) |
|---|---|
| Bupropion | 0.8 |
| Placebo | 1.0 |
Percent loss in Body Mass Index (NCT00414167)
Timeframe: 8 weeks (baseline and 8 weeks)
| Intervention | Percent loss (Mean) |
|---|---|
| Bupropion | 1.8 |
| Placebo | 0.6 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| NB32 | 18.49 |
| Placebo | 5.66 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| NB32 | -1.06 |
| Placebo | -1.47 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| NB32 | -11.87 |
| Placebo | -4.02 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| NB32 | 3.03 |
| Placebo | -0.29 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
| Intervention | percent change (Least Squares Mean) |
|---|---|
| NB32 | -13.48 |
| Placebo | -10.35 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| NB32 | -1.44 |
| Placebo | -0.01 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
| Intervention | percent change (Least Squares Mean) |
|---|---|
| NB32 | -11.20 |
| Placebo | -0.80 |
The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The carbohydrates subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome). (NCT00474630)
Timeframe: Baseline, 56 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| NB32 | -1.48 |
| Placebo | -1.52 |
The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The sweets subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome). (NCT00474630)
Timeframe: Baseline, 56 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| NB32 | -1.97 |
| Placebo | -2.40 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
| Intervention | percent (Least Squares Mean) |
|---|---|
| NB32 | -0.63 |
| Placebo | -0.14 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
| Intervention | percent change (Least Squares Mean) |
|---|---|
| NB32 | -20.91 |
| Placebo | -13.29 |
HOMA-IR= Homeostasis Model Assessment-Insulin Resistance (NCT00474630)
Timeframe: Baseline, 56 weeks
| Intervention | percent change (Least Squares Mean) |
|---|---|
| NB32 | -20.56 |
| Placebo | -14.67 |
IDS-SR= Inventory of Depressive Symptoms-Subject Rated IDS-SR total score is based on 30 items. The total score can range from 0-84, with 0 being no depressive symptoms and 84 being very severe depressive symptoms. A total score ≤ 13 indicates no depression. (NCT00474630)
Timeframe: Baseline, 56 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| NB32 | 0.01 |
| Placebo | -1.60 |
IWQOL-Lite= Impact of Weight on Quality of Life-Lite Questionnaire Total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment (NCT00474630)
Timeframe: Baseline, 56 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| NB32 | 9.27 |
| Placebo | 7.90 |
Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult (NCT00474630)
Timeframe: Baseline, 56 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| NB32 | -11.89 |
| Placebo | -6.91 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| NB32 | 0.03 |
| Placebo | -1.12 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
| Intervention | cm (Least Squares Mean) |
|---|---|
| NB32 | -4.97 |
| Placebo | -2.89 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
| Intervention | percentage of body weight (Least Squares Mean) |
|---|---|
| NB32 | -5.03 |
| Placebo | -1.75 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| NB32 | 44.53 |
| Placebo | 18.87 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| NB32 | 20.72 |
| Placebo | 10.22 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| NB32 | 44.14 |
| Placebo | 26.28 |
Due to pre-specified hypothesis testing design, no formal statistical inference testing was performed. Odds ratio not calculated as there were no subjects in the NB32 group that discontinued due to poor glycemic control. (NCT00474630)
Timeframe: Baseline, 56 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| NB32 | 0 |
| Placebo | 1.89 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| NB32 | 22.26 |
| Placebo | 35.22 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| NB32 | 3.02 |
| Placebo | 1.26 |
(NCT00474630)
Timeframe: Baseline, 56 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| NB32 | 1.89 |
| Placebo | 1.26 |
Due to early termination of the study, the pre-planned 50% interim analysis is considered the primary analysis for outcome measures. (NCT01601704)
Timeframe: Confirmed occurrence of event between Day 1 (randomization) and up to a maximum of 4 years of follow-up
| Intervention | Participants (Count of Participants) |
|---|---|
| NB32 | 17 |
| Placebo | 34 |
Due to early termination of the study, the pre-planned 50% interim analysis is considered the primary analysis for outcome measures. (NCT01601704)
Timeframe: Confirmed occurrence of event between Day 1 (randomization) and up to a maximum of 4 years of follow-up
| Intervention | Participants (Count of Participants) |
|---|---|
| NB32 | 133 |
| Placebo | 142 |
The primary endpoint is the time from randomization to the first confirmed occurrence of any event within the primary MACE composite (defined as cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke). Due to early termination of the study, pre-planned 50% interim analysis is considered the primary analysis for outcome measures. The pre-planned 50% interim analysis was conducted when 50% of the total planned MACE were observed. (NCT01601704)
Timeframe: Confirmed occurrence of event between Day 1 (randomization) and up to a maximum of 4 years of follow-up
| Intervention | Participants (Count of Participants) |
|---|---|
| NB32 | 90 |
| Placebo | 102 |
Due to early termination of the study, the pre-planned 50% interim analysis is considered the primary analysis for outcome measures. (NCT01601704)
Timeframe: Confirmed occurrence of event between Day 1 (randomization) and up to a maximum of 4 years of follow-up
| Intervention | Participants (Count of Participants) |
|---|---|
| NB32 | 55 |
| Placebo | 57 |
Due to early termination of the study, the pre-planned 50% interim analysis is considered the primary analysis for outcome measures. (NCT01601704)
Timeframe: Confirmed occurrence of event between Day 1 (randomization) and up to a maximum of 4 years of follow-up
| Intervention | Participants (Count of Participants) |
|---|---|
| NB32 | 22 |
| Placebo | 21 |
(NCT00532779)
Timeframe: Baseline, 56 weeks
| Intervention | Percentage of participants (Number) |
|---|---|
| NB16 | 20.17 |
| NB32 | 24.63 |
| Placebo | 7.44 |
(NCT00532779)
Timeframe: Baseline, 56 weeks
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| NB16 | 0.09 |
| NB32 | 0.04 |
| Placebo | -0.86 |
(NCT00532779)
Timeframe: Baseline, 56 weeks
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| NB16 | -2.39 |
| NB32 | -3.24 |
| Placebo | -1.30 |
(NCT00532779)
Timeframe: Baseline, 56 weeks
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| NB16 | 3.36 |
| NB32 | 3.42 |
| Placebo | -0.06 |
(NCT00532779)
Timeframe: Baseline, 56 weeks
| Intervention | percent change (Least Squares Mean) |
|---|---|
| NB16 | -11.84 |
| NB32 | -17.14 |
| Placebo | -4.57 |
(NCT00532779)
Timeframe: Baseline, 56 weeks
| Intervention | mg/dL (Least Squares Mean) |
|---|---|
| NB16 | -3.67 |
| NB32 | -4.41 |
| Placebo | -3.28 |
(NCT00532779)
Timeframe: Baseline, 56 weeks
| Intervention | percent change (Least Squares Mean) |
|---|---|
| NB16 | -7.96 |
| NB32 | -12.69 |
| Placebo | -3.08 |
The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The carbohydrates subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome). (NCT00532779)
Timeframe: Baseline, 56 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| NB16 | -1.85 |
| NB32 | -2.11 |
| Placebo | -1.84 |
The Food Craving Inventory is a 33-item self-report measure designed to assess specific food cravings and is organized into 4 subscales (high fats, sweets, carbohydrates/starches, and fast-food fats). A craving was defined as an intense desire to consume a particular food (or food type) that was difficult to resist over the past month. Subjects rated their frequency of cravings for each of the 33 items using a 5-point scale, where 1=never, 2=rarely, 3=sometimes, 4=often, and 5=always. The sweets subscale consisted of 8 items and the score ranges from 8 (better outcome) to 40 (worse outcome). (NCT00532779)
Timeframe: Baseline, 56 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| NB16 | -2.08 |
| NB32 | -2.62 |
| Placebo | -2.77 |
(NCT00532779)
Timeframe: Baseline, 56 weeks
| Intervention | percent change (Least Squares Mean) |
|---|---|
| NB16 | -28.02 |
| NB32 | -28.98 |
| Placebo | -16.66 |
HOMA-IR= Homeostasis Model Assessment-Insulin Resistance (NCT00532779)
Timeframe: Baseline, 56 weeks
| Intervention | percent change (Least Squares Mean) |
|---|---|
| NB16 | -14.33 |
| NB32 | -20.19 |
| Placebo | -5.90 |
IDS-SR= Inventory of Depressive Symptoms-Subject Rated IDS-SR total score is based on 30 items. The total score can range from 0-84, with 0 being no depressive symptoms and 84 being very severe depressive symptoms. A total score ≤ 13 indicates no depression. (NCT00532779)
Timeframe: Baseline, 56 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| NB16 | 0.02 |
| NB32 | -0.27 |
| Placebo | -0.72 |
IWQOL-Lite= Impact of Weight on Quality of Life-Lite Questionnaire Total score is based on a scale from 0 to 100, with 0 representing the poorest and 100 the best quality of life and where a score of 71-79 indicates moderate impairment (NCT00532779)
Timeframe: Baseline, 56 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| NB16 | 11.68 |
| NB32 | 12.69 |
| Placebo | 8.55 |
Question 19: Generally, how difficult has it been to control your eating? Scoring: 0=not at all difficult; 100=extremely difficult (NCT00532779)
Timeframe: Baseline, 56 weeks
| Intervention | units on a scale (Least Squares Mean) |
|---|---|
| NB16 | -12.49 |
| NB32 | -14.52 |
| Placebo | -8.68 |
(NCT00532779)
Timeframe: Baseline, 56 weeks
| Intervention | mm Hg (Least Squares Mean) |
|---|---|
| NB16 | 0.29 |
| NB32 | -0.11 |
| Placebo | -1.94 |
(NCT00532779)
Timeframe: Baseline, 56 weeks
| Intervention | cm (Least Squares Mean) |
|---|---|
| NB16 | -5.04 |
| NB32 | -6.24 |
| Placebo | -2.46 |
(NCT00532779)
Timeframe: Baseline, 56 weeks
| Intervention | percentage of body weight (Least Squares Mean) |
|---|---|
| NB16 | -5.00 |
| NB32 | -6.14 |
| Placebo | -1.33 |
(NCT00532779)
Timeframe: Baseline, 56 weeks
| Intervention | percentage of participants (Number) |
|---|---|
| NB16 | 39.49 |
| NB32 | 47.98 |
| Placebo | 16.44 |
6 reviews available for bupropion and Overweight
| Article | Year |
|---|---|
Long-Term Efficacy and Safety of Anti-Obesity Treatment: Where Do We Stand?
Topics: Animals; Anti-Obesity Agents; Benzazepines; Bupropion; Humans; Liraglutide; Naltrexone; Obesity; Orl | 2021 |
Current and emerging medications for overweight or obesity in people with comorbidities.
Topics: Anti-Obesity Agents; Bupropion; Cinnamates; Comorbidity; Cyclohexanes; Diabetes Mellitus; Dyslipidem | 2015 |
Naltrexone ER/Bupropion ER: A Review in Obesity Management.
Topics: Adult; Animals; Anti-Obesity Agents; Bupropion; Delayed-Action Preparations; Drug Combinations; Huma | 2015 |
Interventions to Address Medical Conditions and Health-Risk Behaviors Among Persons With Serious Mental Illness: A Comprehensive Review.
Topics: Behavior Therapy; Bipolar Disorder; Bupropion; Cardiovascular Diseases; Diabetes Mellitus; Dopamine | 2016 |
Combination therapy with naltrexone and bupropion for obesity.
Topics: Animals; Bupropion; Dopamine Uptake Inhibitors; Drug Combinations; Humans; Naltrexone; Narcotic Anta | 2011 |
ACS chemical neuroscience molecule spotlight on contrave.
Topics: Anti-Obesity Agents; Bupropion; Clinical Trials, Phase III as Topic; Double-Blind Method; Drug Appro | 2011 |
11 trials available for bupropion and Overweight
| Article | Year |
|---|---|
Validating pre-treatment body mass index as moderator of antidepressant treatment outcomes: Findings from CO-MED trial.
Topics: Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Biomarkers; Body | 2018 |
A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II).
Topics: Adult; Anti-Obesity Agents; Bupropion; Cardiovascular Diseases; Delayed-Action Preparations; Dopamin | 2013 |
Bupropion for overweight women with binge-eating disorder: a randomized, double-blind, placebo-controlled trial.
Topics: Adult; Body Mass Index; Bulimia; Bupropion; Dopamine Uptake Inhibitors; Double-Blind Method; Female; | 2013 |
Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Blood Glucose; Body Weight; Bupro | 2013 |
BMI changes in adolescents treated with bupropion SR for smoking cessation.
Topics: Adolescent; Body Mass Index; Bupropion; Dose-Response Relationship, Drug; Double-Blind Method; Femal | 2016 |
Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors: A Randomized Clinical Trial.
Topics: Aged; Anti-Obesity Agents; Blood Pressure; Body Mass Index; Bupropion; Cardiovascular Diseases; Conf | 2016 |
Naltrexone/Bupropion extended release-induced weight loss is independent of nausea in subjects without diabetes.
Topics: Adult; Anti-Obesity Agents; Body Mass Index; Bupropion; Combined Modality Therapy; Delayed-Action Pr | 2016 |
Rational design of a combination medication for the treatment of obesity.
Topics: Adult; Animal Feed; Animals; Antidepressive Agents; Bupropion; Disease Models, Animal; Drug Therapy, | 2009 |
An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects.
Topics: Adult; Bupropion; Cotinine; Counseling; Dopamine Uptake Inhibitors; Drug Therapy, Combination; Femal | 2010 |
Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
Topics: Adult; Anti-Obesity Agents; Bupropion; Delayed-Action Preparations; Double-Blind Method; Drug Therap | 2010 |
Bupropion versus sertraline in the treatment of depressive patients with binge eating disorder: retrospective cohort study.
Topics: Adult; Antidepressive Agents; Binge-Eating Disorder; Body Mass Index; Bupropion; Depressive Disorder | 2012 |
6 other studies available for bupropion and Overweight
| Article | Year |
|---|---|
Circulating levels of proglucagon-derived peptides are differentially regulated by the glucagon-like peptide-1 agonist liraglutide and the centrally acting naltrexone/bupropion and can predict future weight loss and metabolic improvements: A 6-month long
Topics: Bupropion; Glucagon; Glucagon-Like Peptide 1; Glucagon-Like Peptide 2; Glucagon-Like Peptides; Human | 2023 |
Concurrent Improvement in Both Binge Eating and Depressive Symptoms with Naltrexone/Bupropion Therapy in Overweight or Obese Subjects with Major Depressive Disorder in an Open-Label, Uncontrolled Study.
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Binge-Eating Disorder; Bup | 2017 |
Psychiatric adverse events and effects on mood with prolonged-release naltrexone/bupropion combination therapy: a pooled analysis.
Topics: Anti-Obesity Agents; Bupropion; Double-Blind Method; Drug Combinations; Humans; Mood Disorders; Nalt | 2019 |
Therapies for obesity and medication-associated weight gain.
Topics: Animals; Appetite Depressants; Bariatric Surgery; Benzazepines; Bupropion; Chronic Disease; Combined | 2013 |
[Mysimba, an American appetite suppressant and the logic of the single European market].
Topics: Anti-Obesity Agents; Bupropion; Drug Combinations; Humans; Naltrexone; Obesity; Overweight | 2015 |
Answers to Clinical Questions in the Primary Care Management of People with Obesity: Pharmacologic Management.
Topics: Anti-Obesity Agents; Benzazepines; Body Mass Index; Bupropion; Guidelines as Topic; Humans; Lactones | 2016 |